Table 4.
Phenotypic and genotypic characteristics of methicillin-susceptible Staphylococcus aureus isolates obtained from dog-owning and non-dog-owning healthy households in the central Ohio region
| Genotyping | Phenotyping | Frequency | |
|---|---|---|---|
| USA type | SCCmec | ||
| Human isolates (n = 152) | |||
| USA200 (n = 54) | n.a. | Amp | 31 |
| AmpEryCliInd | 11 | ||
| S | 6 | ||
| EryCliInd | 5 | ||
| AmpEnoCipEryCliInd | 1 | ||
| USA600 (n = 18) | n.a. | Amp | 13 |
| S | 3 | ||
| AmpEryCliInd | 2 | ||
| USA900 (n = 15) | n.a. | Amp | 14 |
| S | 1 | ||
| USA100 (n = 9) | n.a. | AmpEryCliInd | 3 |
| Amp | 2 | ||
| AmpTetDox | 2 | ||
| Ery | 1 | ||
| S | 1 | ||
| USA300 (n = 9) | n.a. | Amp | 4 |
| AmpEry | 2 | ||
| AmpEryCliInd | 2 | ||
| AmpEryTetCliInd | 1 | ||
| USA700 (n = 5) | n.a. | Amp | 4 |
| AmpEryTetCliInd | 1 | ||
| USA1200 (n = 4) | n.a. | AmpEryCliInd | 2 |
| Amp | 1 | ||
| AmpEryTetCliInd | 1 | ||
| EMRSA15 (n = 4) | n.a. | Amp | 4 |
| Novel type (n = 4) | n.a. | Amp | 4 |
| Iberian (n = 2) | n.a. | Amp | 1 |
| AmpEryCliInd | 1 | ||
| Not typable (n = 28) | n.a. | Amp | 12 |
| S | 10 | ||
| Ery | 3 | ||
| AmpEry | 1 | ||
| AmpEryCliInd | 1 | ||
| EryCliInd | 1 | ||
| Dog isolates (n = 8) | |||
| USA600 (n = 3) | n.a. | Amp | 2 |
| AmpEryCliInd | 1 | ||
| USA900 (n = 2) | n.a. | Amp | 2 |
| USA100 (n = 1) | n.a. | Amp | 1 |
| Group C (n = 1) | n.a. | S | 1 |
| Not typable (n = 1) | n.a. | S | 1 |
Amp, Ampicillin; Cli, clindamycin; CliInd, inducible clindamycin; Cip, ciprofloxacin; Dox, doxycycline; Ery, erythromycin; S, pansusceptible; Tet, tetracycline; n.a., not applied.